|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is a need to better understand how cytokines like IL-27, IL-30, and IL-35 interact with one another, and how a developing tumor can exploit these interactions to enhance immune suppression.
|
31681561 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In cancer, IL-27 restricts tumor growth by acting on tumor cells directly, while its role in the tumor microenvironment is still controversially discussed.
|
31637217 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that tumor-infiltrating Tregs (Ti-Tregs) failed to up-regulate CD39 in mice lacking EBI3 subunit of IL-27 or IL-27Ra.
|
30718407 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with high-grade and locally advanced PC, those with IL-30<sup>-/-</sup>tumors, showed distinct intra-tumoral cytotoxic granule-associated RNA binding protein (TIA-1)<sup>+</sup>CD4<sup>+</sup>Tlymphocyte infiltrate, rare Foxp3<sup>+</sup>Tregs and a lower biochemical recurrence rate compared to patients with IL-30<sup>+/+</sup>tumors in which IL-30 is expressed in both tumor cells and infiltrating leukocytes.
|
31366386 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL30 overproduction by PCSLCs promoted tumor onset and development associated with increased proliferation, vascularization, and myeloid cell recruitment.
|
29487200 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a plasmacytoma mouse model, we found that IL-10 was required for AAV-IL-27-mediated tumor rejection.
|
29618655 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Like IFN-γ, IL27 leads to an up-regulation of TAP2 and MHC-I proteins, which mediate increased tumor immune clearance.
|
30040142 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transplant experiments in Ly5.1/5.2 congenic mice revealed that IL27 directly acted on these cells and promoted their differentiation into M1 macrophages, which mobilized into tumors.
|
29093008 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our novel findings indicate that IL-27 directly acts on hematopoietic stem cells and promotes their expansion and differentiation into myeloid progenitors to control infection and to eradicate tumors.
|
29721372 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms.
|
28835457 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages.
|
26868086 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, IL-27 showed a striking capability of up-regulating the expression of PD-L2 and HLA-I on tumor endothelium, whereas it did not modify that of PD-L1 and HLA-II.Our results suggest that cytokine-activated endogenous or adoptively transferred NK cells might support conventional therapies improving the outcome of MM patients.
|
28456791 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.
|
28255204 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the subcutaneous tumorous model of C57/BL6 mouse, there were decreased vessel density and tumor volume when inoculation with IL-27-overexpressed TC-1 cells.
|
28508429 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further analysis showed IL-27 2905T/G genotypes were associated with advanced tumor stages of cervical cancer patients.
|
26662568 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further analysis showed IL-27 2905T/G genotypes were associated with advanced tumor stages of cervical cancer patients.
|
26848614 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical studies have revealed that the immune-regulatory cytokine IL-27 may exert anti-tumor activities in a variety of tumor types without discernable toxicity.
|
24681516 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, IL-27 and poly(I:C) cooperatively augmented TRAIL expression and inhibited tumor growth.
|
24155891 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases.
|
24028178 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that transfection of the IL-27 gene into human pancreatic carcinoma cells could produce antitumor effects in vivo and induction of cell cycle arrest and apoptosis could be the mechanism of IL-27 action in tumor regression.
|
22293948 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo.
|
21801027 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deficiency of either the IL-27 subunit EBV-induced gene 3 or the IL-27 receptor WSX1 in the host animals had no effect on tumor growth inhibition induced by WSX1 expression in tumor cells.
|
19549909 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene transfer of IL-27 to tumor cells has been proven to inhibit tumor growth in vivo by antiproliferation, antiangiogenesis, and stimulation of immunoprotection.
|
19841177 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-27 augmented the expression of IFN regulatory factor (IRF)-1 and IRF-8, which possess tumor suppressor activities, in B16F10 transfectants expressing wild-type WSX-1.
|
18453571 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No or rare p28 expression was detected in normal or tumour B cells.
|
16639698 |
2006 |